Ielizaveta Gorodetska, Anne Offermann, Jakob Püschel, Vasyl Lukiyanchuk, Diana Gaete, Anastasia Kurzyukova, Vera Freytag, Marie-Therese Haider, Christina S Fjeldbo, Simona Di Gaetano, Franziska Maria Schwarz, Shivaprasad Patil, Angelika Borkowetz, Holger H H Erb, Aria Baniahmad, Jovan Mircetic, Heidi Lyng, Steffen Löck, Annett Linge, Tobias Lange, Franziska Knopf, Ben Wielockx, Mechthild Krause, Sven Perner, Anna Dubrovska
Rationale: Current therapies for metastatic osseous disease frequently fail to provide a durable treatment response. To date, there are only limited therapeutic options for metastatic prostate cancer, the mechanisms that drive the survival of metastasis-initiating cells are poorly characterized, and reliable prognostic markers are missing. A high aldehyde dehydrogenase (ALDH) activity has been long considered a marker of cancer stem cells (CSC). Our study characterized a differential role of ALDH1A1 and ALDH1A3 genes as regulators of prostate cancer progression and metastatic growth...
2024: Theranostics